Cann Group (CNGGF) Fair Value & Analysis
Healthcare · US · Market cap $5.5M
Cann Group
CNGGF · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0100 to $0.0036 (−63.8%) since Jun 25, 2026. Share price +126.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0015 – $0.0278 · the $0.0034 price screens below the $0.0036 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Cann Group (CNGGF) currently trades at $0.0034, while our model-based Fair Value estimate is $0.0036 — implying the stock looks roughly 6.6% undervalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $11.3M. Revenue declined 30.1% year over year. It earns a return on equity of 72.6%. Net debt stands at $75.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cann Group reported revenue of $13.3M in FY2025 versus $8.6M in FY2021, a compound +11.5%/yr. Reported net income was −$22.3M in FY2025.
Is CNGGF fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cann Group (CNGGF) undervalued?
What is the fair value of CNGGF?
What is the quality score of CNGGF?
What is the revenue of Cann Group (CNGGF)?
What is the net profit margin of CNGGF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.